Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, July 12, 2017
[ Wed, Jul 12th 2017
] - WOPRAI
Tue, July 11, 2017
[ Tue, Jul 11th 2017
] - WOPRAI
[ Tue, Jul 11th 2017
] - WOPRAI
[ Tue, Jul 11th 2017
] - WOPRAI
[ Tue, Jul 11th 2017
] - WOPRAI
[ Tue, Jul 11th 2017
] - WOPRAI
[ Tue, Jul 11th 2017
] - WOPRAI
[ Tue, Jul 11th 2017
] - WOPRAI
Mon, July 10, 2017
[ Mon, Jul 10th 2017
] - WOPRAI
[ Mon, Jul 10th 2017
] - WOPRAI
[ Mon, Jul 10th 2017
] - WOPRAI
[ Mon, Jul 10th 2017
] - WOPRAI
[ Mon, Jul 10th 2017
] - WOPRAI
[ Mon, Jul 10th 2017
] - WOPRAI
[ Mon, Jul 10th 2017
] - WOPRAI
[ Mon, Jul 10th 2017
] - WOPRAI
[ Mon, Jul 10th 2017
] - WOPRAI
[ Mon, Jul 10th 2017
] - WOPRAI
[ Mon, Jul 10th 2017
] - WOPRAI
David Lebovitz Maintained (ALNY) at Hold with Increased Target to $46 on, Jul 10th, 2017
David Lebovitz of Morgan Stanley, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Hold with Increased Target from $42 to $46 on, Jul 10th, 2017.
David has made no other calls on ALNY in the last 4 months.
There are 2 other peers that have a rating on ALNY. Out of the 2 peers that are also analyzing ALNY, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Esther Rajavelu of "UBS" Initiated at Hold and Held Target at $55 on, Thursday, March 30th, 2017
This is the rating of the analyst that currently disagrees with David
- Do Kim of "BMO Capital" Initiated at Buy and Held Target at $73 on, Monday, April 17th, 2017
Similar Stocks and Investing Articles
[ Fri, Jul 07th 2017
] - WOPRAI
[ Fri, Jun 30th 2017
] - WOPRAI
[ Mon, Apr 24th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Thu, Jan 19th 2017
] - WOPRAI
[ Tue, Nov 10th 2015
] - WOPRAI
[ Thu, Apr 17th 2014
] - WOPRAI
[ Mon, Jul 15th 2013
] - WOPRAI
[ Thu, May 23rd 2013
] - WOPRAI